Free Trial
→ Elon’s BIGGEST warning yet? (From Brownstone Research) (Ad)
OTCMKTS:BVNRY

Bavarian Nordic 11/16/2023 Earnings Report

Bavarian Nordic logo
$8.99 +0.10 (+1.15%)
As of 01:25 PM Eastern
ProfileEarnings History

Bavarian Nordic EPS Results

Actual EPS
$0.14
Consensus EPS
$0.36
Beat/Miss
Missed by -$0.22
One Year Ago EPS
N/A

Bavarian Nordic Revenue Results

Actual Revenue
$201.01 million
Expected Revenue
$228.86 million
Beat/Miss
Missed by -$27.85 million
YoY Revenue Growth
N/A

Bavarian Nordic Announcement Details

Quarter
Date
11/16/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bavarian Nordic's next earnings date is estimated for Friday, August 22, 2025, based on past reporting schedules.

Conference Call Resources

Bavarian Nordic Earnings Headlines

Bavarian Nordic A/S: Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
June 18 at 6:51 AM | finanznachrichten.de
Bavarian Nordic sells its Priority Review Voucher for $160M
June 18 at 5:50 AM | seekingalpha.com
Top Picks for Trump’s Pro-Crypto America
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
June 18, 2025 | Crypto 101 Media (Ad)
Bavarian Nordic A/S: Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
June 12, 2025 | finanznachrichten.de
Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children
June 12, 2025 | finance.yahoo.com
Undiscovered European Gems Including 3 Promising Small Caps
May 12, 2025 | finance.yahoo.com
See More Bavarian Nordic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic and other key companies, straight to your email.

About Bavarian Nordic

Bavarian Nordic (OTCMKTS:BVNRY) A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.

Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.

The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.

The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. 
View Bavarian Nordic Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles